- Dr. Nicole Saphier, a key nominee for surgeon general, markets a supplement containing synephrine, a stimulant prohibited by the US military due to cardiovascular and hepatic risks.
- Health experts warn that synephrine may pose serious liver and heart risks, particularly when used without medical supervision or in unregulated combinations.
- Synephrine, derived from bitter orange, is commonly used in weight-loss and energy products, but has been associated with elevated blood pressure, arrhythmias, and acute liver injury.
- The Department of Defense explicitly bans synephrine in military nutrition products due to its unacceptable health hazards, especially in operational settings.
- Dr. Saphier’s commercial ties to a potentially hazardous supplement have triggered alarm among medical watchdogs and lawmakers, casting doubt on her fitness for the nation’s top health advisory role.
President Donald Trump’s nominee for surgeon general, Dr. Nicole Saphier, markets a dietary supplement containing synephrine—a stimulant prohibited by the U.S. military due to cardiovascular and hepatic risks—amid growing scrutiny over conflicts of interest and public health ethics. While the product remains legally available, health experts warn that synephrine, especially in unregulated combinations, may pose serious liver and heart risks, particularly when used without medical supervision. With the surgeon general expected to uphold rigorous public health standards, Saphier’s commercial ties to a potentially hazardous supplement have triggered alarm among medical watchdogs and lawmakers, casting doubt on her fitness for the nation’s top health advisory role.
Safety Concerns and Scientific Evidence
Synephrine, the active ingredient in Dr. Saphier’s supplement, is derived from bitter orange (Citrus aurantium) and commonly used in weight-loss and energy products. According to a 2021 review published in StatPearls, synephrine has been associated with elevated blood pressure, arrhythmias, and rare but severe cases of acute liver injury. The Department of Defense explicitly bans synephrine in military nutrition products due to these risks, noting in a 2019 memo that the compound ‘poses unacceptable health hazards’ in operational settings where physical stress is high. The FDA does not approve synephrine as a drug but allows its sale as a dietary supplement under the Dietary Supplement Health and Education Act of 1994, which requires no pre-market safety testing. Multiple case studies, including one reported in CDC’s Morbidity and Mortality Weekly Report, have tied synephrine-containing supplements to hospitalizations for hepatotoxicity, especially when combined with caffeine or other stimulants.
Key Players and Their Roles
Dr. Nicole Saphier, a radiologist and frequent Fox News commentator, was nominated by President Trump in early 2025 to serve as the nation’s surgeon general, a role that requires impartiality, scientific integrity, and leadership in public health messaging. She is listed as the medical advisor for ‘Lean+,’ a supplement marketed through a third-party e-commerce brand on Amazon, which includes synephrine as a core ingredient. While Saphier has not publicly disclosed direct financial stakes, her endorsement and professional association with the product raise ethical questions. Amazon has since launched an internal inquiry into whether the product violates its restricted substances policy, particularly given the Pentagon’s stance. Meanwhile, the White House has defended her nomination, with press secretary Karoline Leavitt calling Saphier a ‘powerful asset’ who ‘understands the real health concerns of everyday Americans.’ Public health advocates, including the American Medical Association, have called for a Senate ethics review before confirmation hearings proceed.
Trade-Offs: Regulation, Profit, and Public Trust
The controversy underscores a broader tension between unregulated supplement commerce and public health leadership. On one hand, the $50 billion U.S. dietary supplement industry operates with minimal oversight, allowing medical professionals to endorse products without disclosing risks or financial ties. This creates a lucrative opportunity for doctors with media platforms. On the other, the surgeon general is expected to model evidence-based medicine and avoid conflicts that could undermine health guidance. Endorsing a product with a militarily banned ingredient risks normalizing potentially dangerous substances, especially among vulnerable populations seeking weight-loss solutions. Conversely, outright regulation could face legal and political resistance from industry groups. The dilemma pits individual entrepreneurial rights against institutional credibility, with public trust in health institutions already eroded by misinformation and commercial influence in medicine.
Why the Timing Matters Now
The scrutiny emerges at a critical juncture when the Biden-era push for stricter supplement regulation has stalled, and the Trump administration is reshaping public health leadership. With obesity rates and liver disease on the rise—non-alcoholic fatty liver disease now affects over 25% of Americans—the role of supplements in metabolic health is under greater examination. Saphier’s nomination, coming amid a surge in online wellness commerce, forces a reckoning with how medical authority is monetized. The Guardian’s investigation, published just weeks before scheduled Senate confirmation hearings, has amplified pressure on lawmakers to assess nominee qualifications beyond media visibility. Amazon’s rare intervention signals growing corporate caution around health product liability, while medical associations warn that failing to act could set a precedent for lowering ethical bars in federal health appointments.
Where We Go From Here
In the next six to twelve months, three scenarios could unfold. First, Saphier’s nomination may be withdrawn if Senate hearings reveal deeper financial ties or if Amazon delists the supplement, triggering reputational fallout. Second, she could be confirmed with a pledge to divest or disassociate from the product, though ethics watchdogs argue this won’t erase prior influence. Third, the nomination may stall indefinitely, reflecting broader partisan gridlock over health appointments. Regardless, the incident is likely to reignite legislative efforts to amend the DSHEA, with bipartisan bills expected to propose mandatory safety disclosures for supplements endorsed by federal health officials. Public scrutiny of medical influencers will likely intensify, especially as AI-generated wellness content blurs lines between advice and advertising.
Bottom line — nominating a doctor who profits from a supplement containing a militarily banned and medically questionable ingredient undermines the credibility of the nation’s top health office and demands urgent ethical review before confirmation.
Source: The Guardian